Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18958449 | Compositions And Methods For The Treatment Of Depression | November 2024 | June 2025 | Allow | 7 | 1 | 0 | No | No |
| 18913072 | METHODS OF TREATING MIGRAINE | October 2024 | June 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18811682 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18811674 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18811171 | Compositions and Methods for Treating Hypertension by Modulating Endocrine Activity | August 2024 | November 2024 | Allow | 3 | 1 | 0 | No | No |
| 18796081 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | August 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18778617 | AGENTS THAT TARGET TELOMERASE REVERSE TRANSCRIPTASE (TERT) FOR TREATING CANCER AND SENSITIZING CANCER CELLS TO GENOTOXIC THERAPY | July 2024 | June 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18674761 | PHARMACEUTICAL COMPOSITIONS COMPRISING A TOLFENAMIC ACID | May 2024 | December 2024 | Allow | 7 | 1 | 0 | No | No |
| 18670041 | COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAIN | May 2024 | March 2025 | Allow | 10 | 2 | 1 | No | No |
| 18670627 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | September 2024 | Allow | 4 | 2 | 0 | Yes | No |
| 18659413 | PSYCHOACTIVE MEDICINES AND THEIR USE FOR TREATING PSYCHIATRIC AND NEUROLOGICAL CONDITIONS AND DISORDERS | May 2024 | December 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18620036 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | March 2024 | June 2024 | Allow | 3 | 0 | 0 | No | No |
| 18615452 | Compositions and Methods for Treating Hypertension by Modulating Endocrine Activity | March 2024 | August 2024 | Allow | 5 | 1 | 1 | No | No |
| 18428937 | Compositions And Methods For The Treatment Of Depression | January 2024 | July 2024 | Allow | 5 | 2 | 0 | No | No |
| 18428542 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | January 2024 | October 2024 | Allow | 8 | 2 | 1 | No | No |
| 18422531 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | January 2024 | September 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18421519 | USE OF ATOVAQUONE AND PROGUANIL FOR TREATMENT OF GASTROINTESTINAL DISEASES AND INFLAMMATION | January 2024 | July 2024 | Allow | 6 | 2 | 0 | No | No |
| 18414250 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | January 2024 | May 2025 | Allow | 16 | 1 | 0 | No | No |
| 18397220 | BUPROPION AND DEXTROMETHORPHAN FOR REDUCTION OF SUICIDE RISK IN DEPRESSION PATIENTS | December 2023 | April 2025 | Allow | 16 | 1 | 0 | No | No |
| 18541574 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | December 2023 | March 2025 | Allow | 15 | 3 | 0 | Yes | No |
| 18533619 | METHODS OF INHIBITING CYCLOOXYGENASE (COX) USING TOLTERODINE | December 2023 | October 2024 | Allow | 10 | 2 | 1 | No | No |
| 18510986 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | November 2023 | May 2024 | Abandon | 6 | 1 | 0 | No | No |
| 18510882 | USE OF DEXTROMETHORPHAN IN COMBINATION WITH CYP2D6 AND CYP3A4 ENZYME INHIBITORS FOR THE TREATMENT OF PAIN | November 2023 | November 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18501967 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | November 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18501966 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | November 2023 | May 2024 | Allow | 6 | 1 | 0 | No | No |
| 18385468 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE | October 2023 | June 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18489685 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | October 2023 | June 2024 | Abandon | 8 | 2 | 0 | No | No |
| 18483952 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | October 2023 | May 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18477175 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4 | September 2023 | April 2024 | Allow | 6 | 1 | 0 | No | No |
| 18466595 | NEOADJUVANT CHEMOTHERAPY INDUCES BREAST CANCER METASTASIS THROUGH A TMEM-MEDIATED MECHANISM | September 2023 | January 2025 | Allow | 17 | 1 | 0 | No | No |
| 18239195 | FORMULATIONS AND USES THEREOF | August 2023 | June 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18235986 | COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY | August 2023 | June 2025 | Allow | 22 | 1 | 0 | No | No |
| 18236345 | Composition Comprising an Antiviral Agent and a CXCR4 Selective Antagonist and Methods For Using the Same | August 2023 | May 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18447117 | Dynamic Changes In Circulating Free RNA Of Neural Tumors | August 2023 | September 2024 | Allow | 13 | 0 | 0 | No | No |
| 18230693 | Medical Use of Pharmaceutical Combination or Composition | August 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18359214 | Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate | July 2023 | May 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18355232 | EP4 INHIBITORS AND USE THEREOF | July 2023 | April 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18354215 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | July 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18347970 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | July 2023 | March 2025 | Allow | 21 | 4 | 0 | No | No |
| 18335315 | TOPICAL ROFLUMILAST FORMULATION HAVING ANTIFUNGAL PROPERTIES | June 2023 | April 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18333944 | TREATMENT OF DEPRESSION IN CERTAIN PATIENT POPULATIONS | June 2023 | November 2023 | Allow | 5 | 1 | 0 | No | No |
| 18323714 | BUPROPION AND DEXTROMETHORPHAN FOR REDUCTION OF SUICIDE RISK IN DEPRESSION PATIENTS | May 2023 | December 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18199475 | PHARMACEUTICAL RESINATE COMPOSITIONS AND METHODS OF MAKING AND USING THEREOF | May 2023 | May 2025 | Allow | 24 | 1 | 1 | No | No |
| 18196377 | HUNGER SUPPRESSION | May 2023 | April 2025 | Allow | 23 | 2 | 0 | No | No |
| 18140864 | SOLID DISPERSION FORMS OF RIFAXIMIN | April 2023 | March 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18301754 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | April 2023 | August 2023 | Allow | 4 | 1 | 0 | No | No |
| 18298157 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | April 2023 | June 2025 | Allow | 26 | 1 | 1 | No | No |
| 18190843 | Next Generation FKBP52 Targeting Drugs for the Treatment of Prostate and Breast Cancer | March 2023 | April 2025 | Allow | 25 | 1 | 1 | No | No |
| 18188894 | Compositions And Methods For The Treatment Of Depression | March 2023 | January 2024 | Allow | 10 | 2 | 0 | No | No |
| 18185697 | ENERGY-EFFICIENT SOLVENT-FREE METHOD FOR PRODUCING METAL CHELATES | March 2023 | April 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18117059 | COMPOSITIONS AND METHODS FOR WEIGHT LOSS MAINTENANCE | March 2023 | April 2025 | Allow | 25 | 2 | 0 | No | No |
| 18173291 | COMPOUNDS AND COMBINATIONS THEREOF FOR TREATING NEUROLOGICAL AND PSYCHIATRIC CONDITIONS | February 2023 | June 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18171126 | THERAPEUTIC AGENT FOR FATTY LIVER DISEASE | February 2023 | February 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 18106363 | ANTI-METHANOGENIC LOVASTATIN ANALOGS OR DERIVATIVES AND USES THEREOF | February 2023 | March 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18158268 | TREATMENT OF DEPRESSION IN CERTAIN PATIENT POPULATIONS | January 2023 | May 2023 | Allow | 4 | 1 | 0 | No | No |
| 18095691 | Tamper Resistant Pharmaceutical Formulations | January 2023 | January 2025 | Allow | 24 | 1 | 0 | No | No |
| 18092800 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | January 2023 | August 2024 | Allow | 19 | 0 | 0 | No | No |
| 18087680 | Method and System for Reducing Active Ingredient Potency in Pain-Management Compositions to a Quarter Amount of Approved Levels | December 2022 | March 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18076444 | METHOD FOR TREATMENT OF ROSACEA | December 2022 | January 2024 | Allow | 13 | 2 | 0 | No | No |
| 18062729 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | December 2022 | July 2023 | Allow | 7 | 1 | 0 | No | No |
| 18073885 | USE OF ATOVAQUONE AND PROGUANIL FOR TREATMENT OF GASTROINTESTINAL DISEASES AND INFLAMMATION | December 2022 | January 2025 | Allow | 26 | 2 | 0 | No | No |
| 18061206 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | December 2022 | September 2023 | Allow | 9 | 1 | 0 | No | No |
| 18056975 | METHODS FOR TREATING DEPRESSIVE SYMPTOMS | November 2022 | December 2024 | Allow | 25 | 1 | 0 | No | No |
| 17982745 | CANNABIDIOL AND CHITOSAN COMPOSITIONS AND METHODS OF USING THE SAME | November 2022 | October 2024 | Allow | 24 | 1 | 0 | No | No |
| 18051656 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | November 2022 | June 2023 | Allow | 8 | 1 | 0 | No | No |
| 18051386 | INHIBITION OF SLC TRANSPORTER ACTIVITY OR EXPRESSION TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY | October 2022 | April 2025 | Allow | 29 | 2 | 0 | No | No |
| 17959661 | COMPOSITIONS CONTAINING INOSITOL-STABILIZED ARGININE SILICATE COMPLEXES AND INOSITOL FOR IMPROVING COGNITIVE FUNCTION IN VIDEO GAMERS | October 2022 | February 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17953536 | METHODS OF TREATING MIGRAINE | September 2022 | March 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 17930272 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | September 2022 | March 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 17822039 | ALCOHOL BASED SANITIZER WITH IMPROVED DERMAL COMPATIBILITY AND FEEL | August 2022 | September 2024 | Allow | 25 | 2 | 0 | No | No |
| 17888356 | Method of Treating Renal Cell Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate | August 2022 | August 2023 | Abandon | 12 | 1 | 1 | No | No |
| 17886354 | SmartCore Compositions and Methods | August 2022 | July 2023 | Allow | 11 | 2 | 1 | No | No |
| 17881875 | METHOD FOR INDUCING A SUSTAINED IMMUNE RESPONSE | August 2022 | January 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17817191 | Levodopa and Carbidopa Intestinal Gel and Methods of Use | August 2022 | July 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17880420 | IMMEDIATE RELEASE FORMULATIONS OF CANNABINOIDS | August 2022 | February 2025 | Allow | 31 | 1 | 0 | No | No |
| 17871920 | BUFFER-FREE, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | July 2022 | February 2023 | Allow | 7 | 1 | 1 | No | No |
| 17871924 | TREATMENT OF OPHTHALMOLOGICAL CONDITIONS USING BUFFER-FREE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE | July 2022 | June 2023 | Allow | 11 | 2 | 1 | No | No |
| 17865609 | METHOD FOR TREATING SICKLE CELL DISEASE USING QUERCETIN-CONTAINING COMPOSITIONS | July 2022 | March 2025 | Allow | 32 | 3 | 0 | No | No |
| 17863967 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | July 2022 | December 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17860246 | MARKERS OF TISSUE AGING AND USES THEREFOR | July 2022 | October 2024 | Allow | 27 | 1 | 0 | No | No |
| 17833315 | Methods Of Treatment Of Inflammation Related Conditions Using Pluripotent Anti-inflammatory And Metabolic Modulators | June 2022 | December 2024 | Allow | 30 | 1 | 0 | No | No |
| 17831926 | STABLE LIQUID FORMULATIONS OF CYCLOPHOSPHAMIDE AND PROCESSES TO PREPARE THE SAME | June 2022 | October 2024 | Allow | 28 | 1 | 0 | No | No |
| 17663826 | SIRNA, MEDICAL COMPOSITIONS, AND METHODS FOR TREATING TYPE II DIABETES USING THE SAME | May 2022 | April 2023 | Allow | 11 | 1 | 1 | No | No |
| 17742417 | Novel compounds for use in treating depression and migraine | May 2022 | September 2024 | Allow | 28 | 2 | 0 | No | No |
| 17730356 | SOLUBILIZATE WITH CURCUMIN AND BOSWELLIA AND XANTHOHUMOL | April 2022 | September 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17726934 | GLYCOGEN OR POLYSACCHARIDE STORAGE DISEASE TREATMENT METHOD | April 2022 | August 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17770543 | KETAMINE TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS | April 2022 | June 2024 | Allow | 26 | 2 | 0 | No | No |
| 17725357 | METHODS OF TREATING MIXED DYSLIPIDEMIA | April 2022 | January 2025 | Abandon | 33 | 2 | 0 | No | No |
| 17723935 | CANNABINOID DERIVATIVES AND METHODS FOR THEIR PREPARATION | April 2022 | June 2024 | Allow | 26 | 1 | 0 | No | No |
| 17723771 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | April 2022 | August 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17699600 | Compositions For Affecting Weight Loss | March 2022 | July 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17655632 | METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE | March 2022 | December 2023 | Allow | 21 | 1 | 1 | No | No |
| 17681997 | USES OF DPP IV INHIBITORS | February 2022 | August 2024 | Allow | 30 | 1 | 1 | No | No |
| 17637455 | USE OF WNT INHIBITOR WNT-C59 IN PREPARATION OF DRUG FOR TREATING SCN5A MUTATION-INDUCED DILATED CARDIOMYOPATHY | February 2022 | June 2023 | Allow | 16 | 1 | 2 | No | No |
| 17672549 | STERILE AQUEOUS CHOLINE SALT COMPOSITIONS | February 2022 | May 2024 | Allow | 27 | 1 | 0 | No | No |
| 17670123 | Compositions And Methods For The Treatment Of Depression | February 2022 | July 2024 | Allow | 29 | 1 | 0 | No | No |
| 17650270 | Methods and Compositions for Reducing Side Effects in Chemotherapeutic Treatments | February 2022 | May 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17588943 | Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The GLA Gene | January 2022 | January 2025 | Allow | 36 | 2 | 0 | No | No |
| 17581354 | ENEMA FOR RECTAL APPLICATION | January 2022 | April 2024 | Allow | 27 | 1 | 0 | No | No |
| 17648046 | METHOD OF TREATMENT | January 2022 | June 2024 | Abandon | 29 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WEDDINGTON, KEVIN E.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 32.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WEDDINGTON, KEVIN E works in Art Unit 1629 and has examined 1,234 patent applications in our dataset. With an allowance rate of 77.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner WEDDINGTON, KEVIN E's allowance rate of 77.8% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by WEDDINGTON, KEVIN E receive 1.53 office actions before reaching final disposition. This places the examiner in the 38% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WEDDINGTON, KEVIN E is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +14.3% benefit to allowance rate for applications examined by WEDDINGTON, KEVIN E. This interview benefit is in the 56% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 36.1% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 74.7% of cases where such amendments are filed. This entry rate is in the 93% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 150.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 88% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.1% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 81.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 51.8% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.4% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 41.7% of allowed cases (in the 97% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.